ATE464904T1 - Pharmazeutische zusammensetzungen mit nep- inhibitoren, inhibitoren des endogenes endothelin produzierenden systems und diuretika - Google Patents

Pharmazeutische zusammensetzungen mit nep- inhibitoren, inhibitoren des endogenes endothelin produzierenden systems und diuretika

Info

Publication number: ATE464904T1
Authority: AT; Austria
Prior art keywords: inhibitors; endogene; diuretics; producing system; pharmaceutical compositions
Prior art date: 2005-02-18

Application number

AT06708348T

Other languages

English (en)

Inventor

Klaus Witte

Dieter Ziegler

Matthias Straub

Yvan Fischer

Original Assignee

Solvay Pharm Gmbh

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2005-02-18

Filing date

2006-02-17

Publication date

2010-05-15

2006-02-17 Application filed by Solvay Pharm Gmbh filed Critical Solvay Pharm Gmbh

2010-05-15 Application granted granted Critical

2010-05-15 Publication of ATE464904T1 publication Critical patent/ATE464904T1/de

Links

239000003112 inhibitor Substances 0.000 title abstract 4
102000002045 Endothelin Human genes 0.000 title abstract 2
108050009340 Endothelin Proteins 0.000 title abstract 2
239000002934 diuretic Substances 0.000 title abstract 2
ZUBDGKVDJUIMQQ-UBFCDGJISA-N endothelin-1 Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(O)=O)NC(=O)[C@H]1NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@@H](CC=2C=CC(O)=CC=2)NC(=O)[C@H](C(C)C)NC(=O)[C@H]2CSSC[C@@H](C(N[C@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N2)=O)NC(=O)[C@@H](CO)NC(=O)[C@H](N)CSSC1)C1=CNC=N1 ZUBDGKVDJUIMQQ-UBFCDGJISA-N 0.000 title abstract 2
229940030606 diuretics Drugs 0.000 title 1
239000008194 pharmaceutical composition Substances 0.000 title 1
208000024172 Cardiovascular disease Diseases 0.000 abstract 1
229940097420 Diuretic Drugs 0.000 abstract 1
102000003729 Neprilysin Human genes 0.000 abstract 1
108090000028 Neprilysin Proteins 0.000 abstract 1
229940121792 Thiazide diuretic Drugs 0.000 abstract 1
239000002598 adenosine A1 receptor antagonist Substances 0.000 abstract 1
238000002648 combination therapy Methods 0.000 abstract 1
230000001882 diuretic effect Effects 0.000 abstract 1
239000011885 synergistic combination Substances 0.000 abstract 1
239000003451 thiazide diuretic agent Substances 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Chemical & Material Sciences (AREA)
Animal Behavior & Ethology (AREA)
Medicinal Chemistry (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Organic Chemistry (AREA)
Cardiology (AREA)
Diabetes (AREA)
Heart & Thoracic Surgery (AREA)
Epidemiology (AREA)
Urology & Nephrology (AREA)
Endocrinology (AREA)
Obesity (AREA)
Hematology (AREA)
Emergency Medicine (AREA)
Child & Adolescent Psychology (AREA)
Hospice & Palliative Care (AREA)
Gastroenterology & Hepatology (AREA)
Pulmonology (AREA)
Vascular Medicine (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

AT06708348T 2005-02-18 2006-02-17 Pharmazeutische zusammensetzungen mit nep- inhibitoren, inhibitoren des endogenes endothelin produzierenden systems und diuretika ATE464904T1 (de)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
EP05101235		2005-02-18
PCT/EP2006/060057 WO2006087371A1 (en)	2005-02-18	2006-02-17	Pharmaceutical compositions comprising nep-inhibitors, inhibitors of the endogenous endothelin producing system and diuretics

Publications (1)

Publication Number	Publication Date
ATE464904T1 true ATE464904T1 (de)	2010-05-15

Family

ID=34938763

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT06708348T ATE464904T1 (de)	2005-02-18	2006-02-17	Pharmazeutische zusammensetzungen mit nep- inhibitoren, inhibitoren des endogenes endothelin produzierenden systems und diuretika

Country Status (13)

Country	Link
EP (1)	EP1853270B1 (de)
JP (1)	JP2008530182A (de)
CN (1)	CN101119718B (de)
AT (1)	ATE464904T1 (de)
AU (1)	AU2006215583B2 (de)
BR (1)	BRPI0608184A2 (de)
CA (1)	CA2596922A1 (de)
DE (1)	DE602006013792D1 (de)
ES (1)	ES2344800T3 (de)
MX (1)	MX2007009977A (de)
PL (1)	PL1853270T3 (de)
RU (1)	RU2409366C2 (de)
WO (1)	WO2006087371A1 (de)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2007054975A1 (en) *	2005-11-08	2007-05-18	Panacea Biotec Ltd	Pharmaceutical compositions for the treatment of cardiovascular and other associated disorders
AR070127A1 (es)	2008-01-11	2010-03-17	Novartis Ag	Pirrolo - pirimidinas y pirrolo -piridinas
RU2570426C2 (ru)	2009-12-18	2015-12-10	Мицубиси Танабе Фарма Корпорейшн	Новое антитромботическое средство
US8993631B2 (en)	2010-11-16	2015-03-31	Novartis Ag	Method of treating contrast-induced nephropathy
JP6004322B2 (ja) *	2012-04-24	2016-10-05	国立大学法人千葉大学	心血管イベントの発症リスクの検査方法
JP6133073B2 (ja) *	2013-02-08	2017-05-24	株式会社三和化学研究所	ループ利尿薬を有効成分とする医薬製剤
CN107072977B (zh) *	2014-12-03	2019-11-22	上海翰森生物医药科技有限公司	Nep抑制剂药物组合及其应用
CN108969521A (zh) *	2017-05-31	2018-12-11	邱正廸	乙酰唑胺治疗脑出血的用途
CN110590695B (zh) *	2019-10-22	2023-03-21	南华大学	苯并氮杂环类化合物及其应用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE19510566A1 (de) *	1995-03-23	1996-09-26	Kali Chemie Pharma Gmbh	Benzazepin-, Benzoxazepin- und Benzothiazepin-N-essigsäurederivate sowie Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende Arzneimittel
DE19750002A1 (de) *	1997-11-12	1999-05-20	Solvay Pharm Gmbh	Phosphonsäure-substituierte Benzazepinon-N-essigsäurederivate sowie Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende Arzneimittel
HUP0103836A3 (en) *	1998-06-02	2003-05-28	Osi Pharmaceuticals Inc Uniond	Pyrrolo[2,3d]pyrimidine compositions and their use
BR0115847A (pt) *	2000-12-01	2004-02-25	Osi Pharm Inc	Compostos especìficos para receptor para adenosina a1, a2a, e a3 e usos dos mesmos
WO2002094176A2 (en) *	2001-05-18	2002-11-28	Solvay Pharmaceuticals Gmbh	Use of compounds with combined nep/mp-inhibitory activity on the preparation of medicaments
BR0212899A (pt) *	2001-09-21	2004-11-03	Novartis Ag	Compostos orgânicos
CL2004000545A1 (es) *	2003-03-18	2005-01-28	Pharmacia Corp Sa Organizada B	Uso de un antagonista de los receptores de aldosterona y un antagonista de receptores de endotelina para el tratamiento o profilaxis de una condicion patologica relacionada con hipertension, disfuncion renal, insulinopatia y enfermedades cardiovascul
CL2004000544A1 (es) *	2003-03-18	2005-01-28	Pharmacia Corp Sa Organizada B	Uso de una combinacion farmaceutica, de un antagonista del receptor de aldosterona y un inhibidor de endopeptidasa neutral, util para el tratamiento y prevencion de una condicion patologica relacionada con hipertension, disfuncion renal, insulinopati
SA04250283B1 (ar) *	2003-09-26	2008-05-26	سولفاي فارماسيتيكالز جي أم بي أتش	مشتقات من amidomethy1-substituted1-(carboxyalkyl)-cyclopentylcarbonylamino-benzazepine-N-acetic acid

2006
- 2006-02-17 WO PCT/EP2006/060057 patent/WO2006087371A1/en not_active Ceased
- 2006-02-17 AT AT06708348T patent/ATE464904T1/de not_active IP Right Cessation
- 2006-02-17 PL PL06708348T patent/PL1853270T3/pl unknown
- 2006-02-17 CA CA002596922A patent/CA2596922A1/en not_active Abandoned
- 2006-02-17 EP EP06708348A patent/EP1853270B1/de not_active Expired - Lifetime
- 2006-02-17 JP JP2007555620A patent/JP2008530182A/ja active Pending
- 2006-02-17 BR BRPI0608184-3A patent/BRPI0608184A2/pt not_active IP Right Cessation
- 2006-02-17 AU AU2006215583A patent/AU2006215583B2/en not_active Ceased
- 2006-02-17 RU RU2007134404/15A patent/RU2409366C2/ru not_active IP Right Cessation
- 2006-02-17 DE DE602006013792T patent/DE602006013792D1/de not_active Expired - Lifetime
- 2006-02-17 MX MX2007009977A patent/MX2007009977A/es active IP Right Grant
- 2006-02-17 CN CN2006800051312A patent/CN101119718B/zh not_active Expired - Fee Related
- 2006-02-17 ES ES06708348T patent/ES2344800T3/es not_active Expired - Lifetime

Also Published As

Publication number	Publication date
ES2344800T3 (es)	2010-09-07
EP1853270A1 (de)	2007-11-14
BRPI0608184A2 (pt)	2009-11-17
EP1853270B1 (de)	2010-04-21
PL1853270T3 (pl)	2010-09-30
JP2008530182A (ja)	2008-08-07
CN101119718A (zh)	2008-02-06
MX2007009977A (es)	2007-09-26
WO2006087371A1 (en)	2006-08-24
AU2006215583B2 (en)	2011-05-12
DE602006013792D1 (de)	2010-06-02
RU2007134404A (ru)	2009-03-27
CN101119718B (zh)	2011-06-15
CA2596922A1 (en)	2006-08-24
RU2409366C2 (ru)	2011-01-20
AU2006215583A1 (en)	2006-08-24

Similar Documents

Publication	Publication Date	Title
BR0110079A (pt)	2002-12-31	Combinação de compostos orgânicos
BRPI0815708A8 (pt)	2019-04-09	composto derivado de benzilbenzeno como inibidor de sglt, composição farmacêutica, e, uso de um composto
BRPI0605921B8 (pt)	2021-05-25	compostos orgânicos, seus métodos de preparo e uso, bem como composições farmacêuticas
EA200801945A1 (ru)	2009-02-27	Пирролотриазинанилиновые пролекарственные соединения, полезные в качестве ингибиторов киназы
MA30725B1 (fr)	2009-09-01	Administration d'inhibiteurs de la dipeptidyl peptidase
NO20045152L (no)	2005-01-24	Ikke-nukleosid-reverstranskriptaseinhibitorer
ATE430747T1 (de)	2009-05-15	2-pyrimidinyl-pyrazolopyridin-erbb- kinaseinhibitoren
CY1111087T1 (el)	2015-06-11	Παραγωγα 5-(βενζ-(ζ)-υλιδενο)-θειαζολιδιν-4-ονης ως ανοσοκατασταλτικοι παραγοντες
CL2007000601A1 (es)	2008-01-25	Compuestos derivados de heterobiciclos pirazolicos, inhibidores de la actividad de proteina tiroxina quinasa; composicion farmaceutica que comprende dichos compuestos; y uso de los compuestos en el tratamiento de una enfermedad hiperproliferativa.
GEP20125691B (en)	2012-11-26	Compounds and compositions as protein kinase inhibitors
BRPI0511616A (pt)	2008-01-02	compostos
TW200833370A (en)	2008-08-16	Pharmaceutical composition containing low substituted hydroxypropylcellulose
BRPI0513901A (pt)	2008-05-20	derivados de uréia cìclicos substituìdos, preparação dos mesmos e uso farmacêutico dos mesmos como inibidores de cinase
UY31145A1 (es)	2009-01-30	Derivado de 17b+ciano-18a-homo-19-nor-androst-4-eno, su uso y medicamento que lo contiene
MY151973A (en)	2014-07-31	Cyclic depsipeptides
UY30846A1 (es)	2008-07-31	Derivados de oxindol sustituidos, medicamentos que los comprenden y uso de los mismos
CY1114735T1 (el)	2017-01-25	Θεραπευτικες συνθεσεις οι οποιες περιεχουν εναν ειδικο ανταγωνιστη του υποδοχεα της ενδοθηλινης και εναν αναστολεα της pde5
EA200401227A1 (ru)	2005-04-28	Система доставки лекарства с контролируемым высвобождением, включающая правастатин
CY1112451T1 (el)	2015-12-09	Μεθοδος για μειωση γαστρεντερικης τοξικοτητας λογω της χορηγησης τεγκαφουρης
CL2007000595A1 (es)	2008-01-04	Compuestos derivados de piperidina; composicion farmaceutica y uso para el tratamiento y/o profilaxis de enfermedades seleccionadas entre hipertension, insuficiencia cardiaca congestiva e insuficiencia renal entre otras.
UA95103C2 (ru)	2011-07-11	Замещенные арилсульфонамиды в качестве противовирусных средств
AR058085A1 (es)	2008-01-23	Sal de dihidrogeno fosfato de un antagonista del receptor de prostaglandina d2. composiciones farmaceuticas.
ATE464904T1 (de)	2010-05-15	Pharmazeutische zusammensetzungen mit nep- inhibitoren, inhibitoren des endogenes endothelin produzierenden systems und diuretika
BRPI0512379A (pt)	2008-03-11	composições farmacêuticas compreendendo inibidores de nep, inibidores do sistema de produção de endotelina endógena e antagonista do receptor at1
CL2007001826A1 (es)	2008-01-18	Compuestos derivados de 2-(amino-sustituido)-benzotiazol-sulfonamida, inhibidores de proteasa, en particular, inhibidores de proteasa de vih; composicion farmaceutica; y uso para tratar o combatir una infeccion o enfermedad asociada con la infeccion de un retrovirus resistente a multiples farmacos.

Legal Events

Date	Code	Title	Description
2010-10-15	RER	Ceased as to paragraph 5 lit. 3 law introducing patent treaties